First GLP‑1 Pill Approved

GLP-1 drugs mimic a gut hormone that helps people feel full and eat less; until late 2025, the weight-loss versions approved in the U.S. were shots. In December 2025, the Food and Drug Administration cleared a 25-mg Wegovy tablet, making oral semaglutide the first approved GLP-1 pill for chronic weight management. (fda.gov) The tablet is approved for adults with obesity, or adults who are overweight and have at least one weight-related condition. The label also says semaglutide is approved to cut the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (fda.gov) The approval rested in part on the phase 3 OASIS 4 trial, a 71-week, double-blind study that enrolled 307 adults without diabetes at 22 sites in four countries. Participants were assigned in a 2-to-1 ratio to take oral semaglutide 25 mg once daily or placebo, alongside lifestyle changes. (nejm.org) By week 64, people taking the pill had lost an estimated 13.6% of body weight on average, versus 2.2% with placebo. The semaglutide group was also more likely to hit 5%, 10%, 15%, and 20% weight-loss thresholds, according to the New England Journal of Medicine report. (nejm.org) The trial also found better physical-function scores in the treatment group, and Novo Nordisk’s trial materials reported improvements in cardiometabolic risk factors such as measures tied to heart and metabolic health. Gastrointestinal side effects were common: 74.0% with oral semaglutide versus 42.2% with placebo. (nejm.org) (novonordisk.com) The pill enters a market that had already been reshaped by injectable obesity drugs from Novo Nordisk and Eli Lilly. AJMC reported on April 1, 2026, that the Food and Drug Administration had also approved Lilly’s oral GLP-1 drug orforglipron for obesity, adding another pill to the same race. (ajmc.com) Cost and coverage remain central to how far the new option spreads. Novo Nordisk said on February 24, 2026, that it cut U.S. list prices for Wegovy, Ozempic, and Rybelsus, and on March 31, 2026, it announced a multi-month subscription program for FDA-approved Wegovy. (novonordisk-us.com) Safety warnings did not disappear with the switch from shot to pill. The prescribing information carries a boxed warning about thyroid C-cell tumors seen in rodents and says the drug should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (fda.gov) The immediate change is simple: a category built around weekly injections now has an approved daily tablet. Whether that expands treatment in practice will depend less on the chemistry than on price, coverage, and how many patients can tolerate taking it long term. (fda.gov) (novonordisk-us.com)